Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind Phase III trial of FOLF(HA)iri vs FOLFIRI in metastatic colorectal cancer
2010-020348-36Phase 3Completed
- Sponsor
- Alchemia Oncology
- Start
- Oct 2010
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HyCAMP in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Alchemia Oncology. Primary endpoint: progression-free survival. Started Oct 2010; status: completed.
02
Drugs
HyCAMP
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-020348-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020348-36.